TenderlineUK
Procurement Intelligence
Search
Find a TenderAwarded without competitionTransparency notice
Published 19 Oct 2026, 14:44 BST

Official UK procurement notice

EMBED 3.0 - Improvement of Formulations

Official notice

Authority: Cardiff University (Education)

Direct award
Sectors: Research & Development (R&D) (73) Delivery: Wales (UKL22)
Awarded value£187,587published award · exc. VAT
Award in standstill Not publishedno call for competition
Award (standstill) to ProMed Pharma, LLC

What is being bought

Published requirement description

The B&M Gates Foundation (funder) have reviewed the work with the EMBED research team, undertaken with the manufacturer ProMed, and have decided that to push the EMBED 3.0 project into its next stage (EMBED 4.0 – Human Trials), they’ll need to demonstrate their ability to vary the additional batches offer a more robust mechanism for the medications to enter patients. The additional work has been again funded by the foundation for the purpose of increasing the viability of the delivery method (technology developed as part of EMBED) - Previous direct award for the initial development via Regulation 41 - Schedule 5, para 2.

The lotProcurement structure

single lot · no lot value published
Lot #1Awarded
Delivery: Wales
73000000 Research and development services and related consultancy services

Procedure terms & legal framework

From the official record
Procedure method
Direct award
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Notice status
Awarded without competition
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Stand-alone contract (no framework)
Competition type
Direct award (no call for competition)
GPA / WTO covered
Unspecified in notice
Recurring procurement
Unspecified in notice
First published
19 Oct 2026, 14:44 BST
Last source update
19 Oct 2026, 14:44 BST
FTS notice number
2026/S 000-098562
Latest notice
Transparency notice (UK5)
Delivery area
Wales (UKL22)
Official registry OCID
ocds-h6vhtk-078aee Find a Tender
Why no open competition
Prototypes Development
Published justification

The company chosen has helped develop the technology as part of B&M Gates Foundation EMBED 3.0 project. The project is likely to be taken forward, however the funder has asked for some improvements to be made to increase the likelihood of success in a potential next stage entering human trials. We therefore must stay with the previously used company as they are familiar with the novel/prototype equipment, and moving at this point would be entirely unfeasible, even if there were alternatives available.

Review and risk notes
Risks

Milestone payments ensure each improvement is completed to the satisfaction of the funder and customer before payment can be made.

Notice history

2 events · 1 release on Find a Tender · since 19 Oct 2026
  1. Transparency notice published
    19 Oct 2026, 14:44 BST
    UK5
  2. Contract signature expected
    30 Oct 2026, 23:59 GMT
    scheduled

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast
Awards 1some still in standstill
Awarded value £187,5871 award exc. VAT
Awarded toValueDateStatus
ProMed Pharma, LLC2 Nov 2026 – 31 Dec 2026£187,587—Standstill

Contracting authority & participating public bodies

Cardiff University

Contracting authorityPublic authority - sub-central governmentWelsh devolved regulations apply GB-PPON: PHVT-4343-HWYR Procurement Services, Cardiff, Wales, CF24 4HQContact email

Bidders & participating suppliers

1 commercial party on the notice
  • ProMed Pharma, LLCAwarded supplierGB-PPON: PRNX-3276-XWMG 6765 Wedgwood Road, Maple Grove, MN 55311 USA, Minneapolis, US, MN 55311, USContact email

Official documents & specifications (1)

Official links; attachments are not copied

Notices published for this procedure

  • Transparency notice awardTransparency noticeUK5Transparency notice on Find a Tender